Cargando…

Changes in Helicobacter pylori Treatment from Discovery to Nowadays: A High-Level Analysis of PubMed Publications

BACKGROUND: Since the discovery of Helicobacter pylori (H. pylori) 40 years ago, treatment options have changed dramatically adjacent to new drugs development and the emergence of multi-drug resistance. In this study, we aimed to assess published literature on treatment regimens for H. pylori in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Klang, Eyal, Soffer, Shelly, Barash, Yiftach, Shachar, Eyal, Lahat, Adi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939865/
https://www.ncbi.nlm.nih.gov/pubmed/35330691
http://dx.doi.org/10.2147/CEG.S342048
_version_ 1784672814617329664
author Klang, Eyal
Soffer, Shelly
Barash, Yiftach
Shachar, Eyal
Lahat, Adi
author_facet Klang, Eyal
Soffer, Shelly
Barash, Yiftach
Shachar, Eyal
Lahat, Adi
author_sort Klang, Eyal
collection PubMed
description BACKGROUND: Since the discovery of Helicobacter pylori (H. pylori) 40 years ago, treatment options have changed dramatically adjacent to new drugs development and the emergence of multi-drug resistance. In this study, we aimed to assess published literature on treatment regimens for H. pylori in the past four decades, with regards to specific drug resistance and geographic distribution. METHODS: We have queried PubMed for all available H. pylori-related entries published during 1987–2020. For each entry, we retrieved the title, abstract, and keywords. Two gastrointestinal specialists decided in consensus on a list of terms to classify entries. The terms specify types of treatment and different types of regimens. Annual trends of publications were plotted for different treatment types and sub-analyses. RESULTS: Overall, 47,170 H. pylori-related entries were published between 1987 and 2020. Medication treatment showed the highest number of total publications 6183/47,170 (13.1%), followed by antibiotics 5493/47,170 (11.6%), and probiotic which was substantially lower (0.7%). For treatment regimens type, triple therapy had the highest number of publications 2400/47,170 (5.1%) followed by sequential therapy 342/47,170 (0.7%), and bismuth quadruple therapy 115/47,170 (0.2%). Analysis by antibiotic resistance showed that clarithromycin treatment had the highest number of publications 3537/47,170 (7.5%). Since 2013, there is a steep upward slope (5.1±0.7 publications/year, p < 0.001) for publications originating from China. CONCLUSION: Our findings reflect the changes of the commonly prescribed regimens along the years, following the occurrence and the rise of H. pylori antibiotic resistance. In recent years, there is a steep rise in publications in countries with policies of screening and eradication for gastric cancer prevention, which is currently not applied in Western countries. A text-mining analysis of H. pylori publications contributes to the understanding of treatment options and development trends worldwide.
format Online
Article
Text
id pubmed-8939865
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-89398652022-03-23 Changes in Helicobacter pylori Treatment from Discovery to Nowadays: A High-Level Analysis of PubMed Publications Klang, Eyal Soffer, Shelly Barash, Yiftach Shachar, Eyal Lahat, Adi Clin Exp Gastroenterol Original Research BACKGROUND: Since the discovery of Helicobacter pylori (H. pylori) 40 years ago, treatment options have changed dramatically adjacent to new drugs development and the emergence of multi-drug resistance. In this study, we aimed to assess published literature on treatment regimens for H. pylori in the past four decades, with regards to specific drug resistance and geographic distribution. METHODS: We have queried PubMed for all available H. pylori-related entries published during 1987–2020. For each entry, we retrieved the title, abstract, and keywords. Two gastrointestinal specialists decided in consensus on a list of terms to classify entries. The terms specify types of treatment and different types of regimens. Annual trends of publications were plotted for different treatment types and sub-analyses. RESULTS: Overall, 47,170 H. pylori-related entries were published between 1987 and 2020. Medication treatment showed the highest number of total publications 6183/47,170 (13.1%), followed by antibiotics 5493/47,170 (11.6%), and probiotic which was substantially lower (0.7%). For treatment regimens type, triple therapy had the highest number of publications 2400/47,170 (5.1%) followed by sequential therapy 342/47,170 (0.7%), and bismuth quadruple therapy 115/47,170 (0.2%). Analysis by antibiotic resistance showed that clarithromycin treatment had the highest number of publications 3537/47,170 (7.5%). Since 2013, there is a steep upward slope (5.1±0.7 publications/year, p < 0.001) for publications originating from China. CONCLUSION: Our findings reflect the changes of the commonly prescribed regimens along the years, following the occurrence and the rise of H. pylori antibiotic resistance. In recent years, there is a steep rise in publications in countries with policies of screening and eradication for gastric cancer prevention, which is currently not applied in Western countries. A text-mining analysis of H. pylori publications contributes to the understanding of treatment options and development trends worldwide. Dove 2022-03-18 /pmc/articles/PMC8939865/ /pubmed/35330691 http://dx.doi.org/10.2147/CEG.S342048 Text en © 2022 Klang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Klang, Eyal
Soffer, Shelly
Barash, Yiftach
Shachar, Eyal
Lahat, Adi
Changes in Helicobacter pylori Treatment from Discovery to Nowadays: A High-Level Analysis of PubMed Publications
title Changes in Helicobacter pylori Treatment from Discovery to Nowadays: A High-Level Analysis of PubMed Publications
title_full Changes in Helicobacter pylori Treatment from Discovery to Nowadays: A High-Level Analysis of PubMed Publications
title_fullStr Changes in Helicobacter pylori Treatment from Discovery to Nowadays: A High-Level Analysis of PubMed Publications
title_full_unstemmed Changes in Helicobacter pylori Treatment from Discovery to Nowadays: A High-Level Analysis of PubMed Publications
title_short Changes in Helicobacter pylori Treatment from Discovery to Nowadays: A High-Level Analysis of PubMed Publications
title_sort changes in helicobacter pylori treatment from discovery to nowadays: a high-level analysis of pubmed publications
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939865/
https://www.ncbi.nlm.nih.gov/pubmed/35330691
http://dx.doi.org/10.2147/CEG.S342048
work_keys_str_mv AT klangeyal changesinhelicobacterpyloritreatmentfromdiscoverytonowadaysahighlevelanalysisofpubmedpublications
AT soffershelly changesinhelicobacterpyloritreatmentfromdiscoverytonowadaysahighlevelanalysisofpubmedpublications
AT barashyiftach changesinhelicobacterpyloritreatmentfromdiscoverytonowadaysahighlevelanalysisofpubmedpublications
AT shachareyal changesinhelicobacterpyloritreatmentfromdiscoverytonowadaysahighlevelanalysisofpubmedpublications
AT lahatadi changesinhelicobacterpyloritreatmentfromdiscoverytonowadaysahighlevelanalysisofpubmedpublications